NIM
CRSP icon

Needham Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Needham Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5,500
Closed -$233K – 105
2020
Q1 		$233K Hold
5,500
– – 0.07% 104
2019
Q4 		$335K Buy
+5,500
New +$300K 0.09% 88

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Needham Investment Management's CRSP Position: Q2 2020 in Review

Needham Investment Management sold out of CRISPR Therapeutics (CRSP) in Q2 2020, closing a stake of 5,500 shares — an estimated $233K sold.

Needham Investment Management first reported a position in CRSP in Q4 2019 and held it in 2 quarters. The position peaked at $335K in Q4 2019. 276 funds tracked by Wall St. Rank hold CRSP as of Q2 2020.

  • Needham Investment Management reported no remaining CRISPR Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Needham Investment Management sold 5,500 CRISPR Therapeutics shares in Q2 2020, an estimated $233K.
  • Needham Investment Management first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 2 quarters.
  • Needham Investment Management's CRISPR Therapeutics position peaked at $335K in Q4 2019.
  • 276 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2020.

Based on Needham Investment Management's 13F filing for Q2 2020, filed 14 Aug 2020.